



## Editas Medicine to Participate in Upcoming Investor Conferences

August 29, 2019

CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following investor conferences in September:

### **Citi 14<sup>th</sup> Annual Biotech Conference**

Format: Hematology Panel  
Date: Thursday, September 5, 2019  
Time: 8:00 a.m. ET  
Location: Boston, MA

### **Morgan Stanley 17<sup>th</sup> Annual Global Healthcare Conference**

Format: Fireside Chat  
Date: Monday, September 9, 2019  
Time: 2:15 p.m. ET  
Location: New York, NY

The events will be webcast live and may be accessed on the Editas Medicine website in the Investors and Media section. Archived recordings will be available for approximately 30 days following the events.

### **About Editas Medicine**

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit [www.editasmedicine.com](http://www.editasmedicine.com).

### **Contacts:**

#### **Investors**

Mark Mullikin  
(617) 401-9083  
[mark.mullikin@editasmed.com](mailto:mark.mullikin@editasmed.com)

#### **Media**

Cristi Barnett  
(617) 401-0113  
[cristi.barnett@editasmed.com](mailto:cristi.barnett@editasmed.com)



Source: Editas Medicine, Inc.